Arylation Reagents

Deutsche Ausgabe: DOI: 10.1002/ange.201602569
Internationale Ausgabe: DOI: 10.1002/anie.201602569

NH-Heterocyclic Aryliodonium Salts and their Selective Conversion into *N*1-Aryl-5-iodoimidazoles

Yichen Wu, Susana Izquierdo, Pietro Vidossich, Agustí Lledós, and Alexandr Shafir**

Abstract: *The synthesis of N-arylimidazoles substituted at the sterically encumbered 5-position is a challenge for modern synthetic approaches. A new family of imidazolyl aryliodonium salts is reported, which serve as a stepping stone on the way to selective formation of N1-aryl-5-iodoimidazoles. Iodine acts as a "universal" placeholder poised for replacement by aryl substituents. These new λ^3-iodanes are produced by treating the NH-imidazole with $ArI(OAc)_2$, and are converted to N1-aryl-5-iodoimidazoles by a selective copper-catalyzed aryl migration. The method tolerates a variety of aryl fragments and is also applicable to substituted imidazoles.*



Scheme 1. Examples of common imidazole *N*-arylation strategies (**A**) and the relay arylation (**B**) proposed here.

Imidazole is a ubiquitous heterocyclic core present in a wide range of biologically relevant molecules.[1] Although the synthesis of imidazole derivatives is commonly accomplished through a variety of cyclization routes, it is often desirable to obtain a particular derivative starting from a preformed heterocyclic ring. For this reason, imidazole derivatization has been the focus of attention from a number of laboratories. A particularly common challenge is the selective construction of the 1,4- and 1,5-disubstituted imidazoles. Thus, the *NH*-arylation of an imidazole substituted at the C4(5) position tends to produce a mixture of isomers favoring the sterically less encumbered *NH* position, and thus, the 1,4-substitution pattern.[2,3] This bias was recently perfected by Buchwald et al. using a highly bulky biaryl phosphine ligand in palladium-catalyzed imidazole *N*-arylation.[3b] A similar preference for the less encumbered *NH* position can also be seen in the oxidative Chan–Lam *N*-arylation of imidazole (Scheme 1 A).[4]

However, a challenge remains to selectively access the corresponding 1,5-disubstituted imidazoles. Progress made in recent years includes the use of well-designed protection/deprotection strategies,[5] and the C5-selective *CH*-borylation[6] and *CH*-arylation[7] reactions.

Herein, we present a new route to a versatile class of precursors for 1,5-disubstituted imidazoles. Specifically, the *N*1-aryl-5-iodoimidazoles are produced via a relay in which a hypervalent iodoarene fragment[8] serves as a trampoline for aryl transfer to the proximal *NH* site (Scheme 1 B). We reasoned that if the iodane ***I*** could be generated, it can then undergo a phenyl transfer to produce ***II***, perhaps akin to the intramolecular *O*- and *N*-arylation observed in iodonium ylides.[9] Somewhat surprisingly, the *NH*-heterocyclic λ^3-iodanes have only received limited attention beyond the early work by Neiland et al. in the 1970's.[10,11] However, recent reports highlight the promise of hypervalent iodine reactivity in azole functionalization, including via heterocyclic λ^3-iodanes.[12]

In particular, we found only a single precedent for an imidazolyl-λ^3-iodane derived from unprotected imidazole;[13] this species, however, was described as an imidazole fragment bound to iodine through the nitrogen atom.[13a] A reaction between $PhI(O_2CCF_3)_2$ and imidazole (2 equiv) in acetonitrile at room temperature produced a white precipitate identified as [PhI(Imid)][TFA] salt, **1a** (58%; TFA = trifluoroacetate). However, the presence of just two imidazolic resonances in ^{1}H NMR (1H each) strongly suggested a *CH* rather than *NH* functionalization of the imidazole. Accordingly, X-Ray crystallography revealed a classical T-shaped diaryliodonium environment, with the imidazole bound to the iodine through the C4(5) carbon atom (Scheme 2). An analogous acetate salt **2a** was obtained by employing $PhI(OAc)_2$. A DFT analysis confirmed that both the C2 and the *N*-bound isomer are higher in energy than the observed C4(5) isomer. An *N*-bound species was found unlikely even as an intermediate on the way to **1a**; rather, the reaction appeared to proceed through a Wheland-type intermediate (see Supporting Information).

While sparingly soluble in $CDCl_3$, **1a** and **2a** dissolved well in MeOH and water. They also underwent a facile deprotonation into zwitterionic **3**, for which both the solid state and DFT structures show an essentially "normal" single C_{imid}–I bond (2.051 and 2.076 Å, respectively, vs. 2.091 Å observed for **1a**). We quickly discovered that the desired iodine-to-nitrogen phenyl transfer does not take place upon

[*] Y. Wu, Dr. S. Izquierdo, Dr. A. Shafir
Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology
Av. Països Catalans 16, 43007 Tarragona (Spain)
E-mail: ashafir@iciq.es
Dr. P. Vidossich, Prof. Dr. A. Lledós
Departament de Química, Universitat Autònoma de Barcelona
08193 Cerdanyola del Vallès (Spain)
E-mail: agusti@klingon.uab.es
Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under http://dx.doi.org/10.1002/anie.201602569.



Scheme 2. Formation and structures of the imidazole-based λ^3-iodanes and of the neutral (betaine) **3**. Gibbs Energies (kcal mol^{-1}) in CH_3CN.

heating **1a**, **2a**, or **3** in CH_2Cl_2, with or without Cs_2CO_3. Consistently, only a high energy transition state (35.6 kcal mol^{-1}) could be identified for the direct (non-catalyzed) iodine-to-nitrogen 1,3 phenyl migration in **3** (Scheme 3).



Scheme 3. Reaction path modelled for uncatalyzed 1,3 phenyl migration.

Gratifyingly, the addition of 5 mol% of $Cu(OTf)_2$ did allow for the formation of two regioisomeric *N*-phenyl iodoimidazoles, and a moderate selectivity for the more hindered **4a** was achieved in fluorinated alcohols (Table 1, runs 1–3; both isomers confirmed by X-Ray diffraction). The use of Cs_2CO_3 in hexafluoroisopropanol (HFIP) led to a combined yield of 86% with a 4:1 ratio in favor of **4a** (run 4). This ratio was further improved by employing catalytic amounts of certain heterocyclic additives (runs 5–7). For example, the use of 20 mol% of *N*-Me-benzimidazole (run 6) led to an 8:1 selectivity and a 93% yield.

It was subsequently found that the highest yields of **2** were achieved in trifluoroethanol[14] and, notably, MeOH solvents.

Table 1: Copper-catalyzed iodine-to-nitrogen phenyl transfer in **2a**.[a]



Run	Base	Solvent	Additive	Yield [%][b]	**4a**/**5a**[b]
1	–	CH_2Cl_2	–	39	0.1:1
2	–	CF_3CH_2OH	–	51	1.5:1
3	–	HFIP	–	53	4.2:1
4	Cs_2CO_3	HFIP	–	86	4.1:1
5	Cs_2CO_3	HFIP	4-methylimidazole	90	7.3:1
6	Cs_2CO_3	HFIP	benzimidazole	90	8.4:1
7	Cs_2CO_3	HFIP	*N*-Me-benzimidazole	93	8.0:1

[a] Using **2a** (0.5 mmol), $Cu(OTf)_2$ (5 mol%), and base (1.6 equiv, if any) in solvent (2.6 mL). [b] Total yield (%**4a** + %**5a**) and the ratio, as determined by GC.

However, CH_3CN remained convenient for large scale applications because of favorable product precipitation, as seen in the synthesis of a 23 g batch of **2a** (Supporting Information). All the aryl(imidazolyl)-λ^3-iodanes, **2**, exhibited the corresponding Ar-I(Imid)$^+$ cation in the HR (ESI+) mass spectra. These species were subsequently transformed into the *N1*-aryl-5-iodoimidazole, **4,** with good selectivities. As previously observed for **4a**, in all cases a characteristic ^{13}C resonance at 71–73 ppm was observed for the ^{13}C-I unit in **4**, which is approximately 10 ppm lower than in the corresponding 1,4 species **5** (82–85 ppm). Given the synthetic potential of **4a**, the method was extended to structurally diverse aryl(imidazolyl)-λ^3-iodanes (Table 2). The most robust protocol involves the use of 20 mol% of *N*-Me-benzimidazole in combination with 5 mol% of $Cu(OTf)_2$.

The improved selectivity achieved with these additives is likely to be due to the formation of copper-heterocycle complexes. Indeed, best results were achieved by pre-mixing $Cu(OTf)_2$ with the additive and base for 20 min, presumably favoring complex formation. We observed that, while $Cu(OTf)_2$ alone did not dissolve in HFIP, a green solution formed upon addition of *N*-Me-benzimidazole.

Both electron-donating and mildly electron-withdrawing substituents were well tolerated on the aryl fragment (**4b–i**, Table 2). In fact, even a di-*ortho* substitution was tolerated, as illustrated in the successful synthesis of the highly hindered *N*-mesityl-5-iodoimidazole, **4j**. We were particularly pleased with the successful incorporation of a second heterocycle, as in the 2- and 3-thienyl derivatives **4k** and **4l**. The 4-iodobiphenyl and 2-iodonaphthalene derivatives could also be obtained in 70% and 74% yield, respectively (**4m** and **4n**). In the case of the 4-Me-imidazolyl iodane **2o**, a 13:1 **4**/**5** selectivity was achieved, affording the target **4o** in an 87% yield. In this case, selectivity evidently benefited from hindrance at the competing *N*-site. The aryl transfer in the 2-Me derivative **2p** was less efficient, providing **4p** in 31% yield. The method was also applied to produce an 82% of the 4,5-diiodo derivative **4q**. In general, chromatographic separation between **4** and **5** proved straightforward.

As mentioned earlier (see Scheme 1), the high selectivity towards **4** stems from an intramolecular aryl migration from iodine to the proximal nitrogen.[15] Accordingly, a crossover experiment between **2a**-d_2 and **2c** revealed a predominant formation of **4a**-d_2 and **4c**, as expected for an intramolecular process (Scheme 4A).[16] Small amounts of the 1,4 isomers were also produced, for which full aryl/imidazole scrambling was observed, indicating their origin in a bimolecular process. Indirect support for an intramolecular process was also obtained from the poor performance of the pyrazole-derived iodane **6** (< 15% yield, Scheme 4B), which lacks a proximal *NH* site.

We envisaged that **3** (formed upon deprotonation of **2**), binds a Cu^I-OTf fragment through *N1* (Scheme 5).[17,18] Indeed, despite employing a Cu^{II} precatalyst, the true catalytic species is likely a Cu^I center.[18,19] The inclusion of MeOH in the coordination sphere of copper (as a stand-in solvent molecule) was found to be beneficial to properly describe the copper intermediate, and given that the process was already moderately selective (up to 4:1) in the absence of

Table 2: Scope of the relay synthesis of *N*1-aryl-5-iodoimidazoles **4**.



structure **2**		yield **2**[a]	yield **4**[b]	**4**/**5**[c]	structure **4**
	**2a**, R = H **2b**, R = OMe **2c**, R = Me **2d**, R = Cl **2e**, R = OCF_3	87% (78%) 81% (62%) 91% (76%) 81% (68%) 91% (72%)	**4a**, 74% **4b**, 72% **4c**, 75% **4d**, 60% **4e**, 47%	8.1:1 9.8:1 8.5:1 8.4:1 11.6:1[d]	
	**2f**, R = OMe, **2g**, R = Br	81% (64%) 87% (85%)	**4f**, 77% **4g**, 62 %	9.8 :1 8.2:1[e]	
	**2h**	67% (57%)	**4h**, 85%	8.5:1	
	**2i**	96% (71%)	**4i**, 61%	13.0:1[d]	
	**2j**	90% (47%)	**4j** 51%	9.4:1	
	**2k**	75% (80%)	**4k**, 78%	11.8:1[e]	
	**2l**	74% (72%)	**4l**, 79%	13.5:1	
	**2m**	83% (79%)	**4m**, 70%	10.4:1	
	**2n**	82% (76%)	**4n**, 74%	5.6:1	
	**2o**	79% (64%)	**4o**, 87%	13.0:1[f]	
	**2p**	90% (59%)	**4p**, 31%	4.4:1	
	**2q**	(73%)	**4q**, 82%	--	

[a] ^{1}H NMR yield (isolated yield). [b] Yield of isolated products. [c] **4**/**5** ratio determined by GC. [d] Benzimidazole (20 mol%) as additive. [e] 4-methylimidazole (20 mol%) as additive. [f] Ar-I(imid)$^+$OAc$^-$ was added before injection of the solvent; no additive was used.



Scheme 4. Crossover experiment (A), and the assay with pyrazole (B).



Scheme 5. A DFT profile for the Cu^I-catalyzed aryl migration. Relative Gibbs energies in methanol (kcal mol^{-1}).

an additive, this initial DFT study was performed in the absence of an added heterocycle. In the first step, the phenyl group in **A** is transferred from iodide to copper, leading to a formal Cu^{III}-phenyl intermediate **B**.[19,20] This step features an activation barrier of 26.2 kcal mol^{-1} (**ts-1**). A Localized Orbital analysis supports the change in copper oxidation state and allows visualization of the flow of electrons (see small green spheres of **ts-1** in Scheme 5 and Supporting Information). The final C–N bond is formed through an essentially barrierless reductive elimination step (Scheme 5, **ts-2**). Given the energetic proximity between **B** and **ts-2**, the mechanism resembles a copper-guided concerted iodine-to-nitrogen phenyl migration. A preliminary investigation also revealed that the coordination of *N*-Me-benzimidazole to the Cu^I center may disfavor the binding of two molecule of **3** to the same copper center, hence enforcing an intramolecular phenyl transfer.[21]

In agreement with Scheme 5, the preformed zwitterionic **3** was also an excellent substrate even in the absence of a base [Eq. (1)].



(1)

The reason for the poor performance of solvents such as CH_2Cl_2 is likely two-fold. The deprotonation of **2** in CH_2Cl_2 appears sluggish, which negatively affects the selectivity, giving rise to bimolecular crossover events (see Supporting Information). Additionally, while the use of **3** in CH_2Cl_2 does render the reaction moderately selective, the rate remains low.

Iodine introduced at the C5 position enabled the synthesis of a wide spectrum of 1,5-imidazole derivatives (Scheme 6). Thus, the 5-alkynyl and 5-aryl derivatives **7** and **8** were prepared by palladium-catalyzed C–C coupling reactions. Additionally, copper-catalyzed C–N bond formation was readily accomplished to give **9**.[22] The 5-iodoimidazole **2a** was also readily converted into an organomagnesium species,[23] which served as a precursor to the 5-formyl and the 5-borylderivatives **10** and **11**.[23b,c]



Scheme 6. Versatility of the 1-aryl-5-iodoimidazoles in the synthesis of 1,5-substituted imidazoles; i) PhCCH, $PdCl_2$/CuI, Ph_3P, Et_3N at 60 °C; ii) tol-$B(OH)_2$, $Pd(OAc)_2$, XanPhos, K_3PO_4, toluene, 120 °C; iii) pyrrolidinone, CuI, Cs_2CO_3, *N*,*N*′-dimethylethylenediamine in dioxane, 105 °C; iv) DMF in THF, −15 °C to R.T. (from Het-MgX); v) from 4a: *i*PrMgCl·LiCl, *i*PrOBPin in THF.

In conclusion, we have shown that the new (*NH*-imidazolyl)aryl iodonium cation, readily obtained from imidazole and aryliodine diacetate, $ArI(OAc)_2$, serves as an excellent stepping stone for the formation of *N*-arylimidazoles bearing an iodine substituent at the strategic C5 position. The method complements common existing methods known to produce the sterically favored 1,4-derivatives. The method was tolerant of a variety of aryl substitution patterns, including mono- or bis-*ortho* substitution. Through subsequent transformation of the iodine group, the newly formed *N*1-aryl-5-iodoimidazole constitutes a valuable precursor to a wide range of products. Experimental and DFT data suggest that selectivity is likely the result of an intramolecular copper-catalyzed iodine-to-nitrogen migration of the aryl fragments.

Acknowledgements

This work was funded by Fundació ICIQ, MINECO (CTQ2013-46705-R, CTQ2014-54071-P and 2014-2018 Severo Ochoa Excellence Accreditation SEV-2013-0319) and the Generalitat de Catalunya (2014 SGR 1192). The CELLEX Foundation is gratefully acknowledged for a postdoctoral contract to S.I. and for support through the CELLEX-ICIQ HTE platform.

Keywords: C–H functionalization · C–N coupling · copper catalysis · hypervalent iodine · imidazoles

How to cite: *Angew. Chem. Int. Ed.* **2016**, *55*, 7152–7156
Angew. Chem. **2016**, *128*, 7268–7272

[1] a) L. Zhang, X. M. Peng, G. L. V. Damu, R. X. Geng, X. H. Zhou, *Med. Res. Rev.* **2014**, *34*, 340–437; b) M. Gaba, C. Mohan, *Med. Chem. Res.* **2016**, *25*, 173–210.

[2] For a review on metal-catalyzed imidazole functionalization, see: F. Bellina, R. Rossi, *Adv. Synth. Catal.* **2010**, *352*, 1223–1276.

[3] For examples, of catalytic imidazole *N*-arylation, see: a) R. A. Altman, E. D. Koval, S. L. Buchwald, *J. Org. Chem.* **2007**, *72*, 6190–6199; b) S. Ueda, M. Su, S. L. Buchwald, *J. Am. Chem. Soc.* **2012**, *134*, 700–706.

[4] a) J. P. Collman, M. Zhong, *Org. Lett.* **2000**, *2*, 1233–1236; b) X. O. Yu, Y. Yamamoto, N. Miyaura, *Chem. Asian J.* **2008**, *3*, 1517–1522; c) for a review, see: K. Sanjeeva Rao, T.-S. Wu, *Tetrahedron* **2012**, *68*, 7735–7754.

[5] a) B. Delest, P. Nshimyumukiza, O. Fasbender, B. Tinant, J. Marchand-Brynaert, F. Darro, R. Robiette, *J. Org. Chem.* **2008**, *73*, 6816–6823; b) E. Van Den Berge, R. Robiette, *J. Org. Chem.* **2013**, *78*, 12220–12223; during the preparation of this manuscript, a method appeared for *N1*-alkylation of unprotected 1,3-azoles (at Amgen); c) S. Chen, R. F. Grace, A. A. Boezio, *Org. Lett.* **2016**, *18*, 16–19.

[6] M. R. Smith, R. E. Maleczka, V. A. Kallepalli, E. Onyeozili, US 7,709,654 B2, May 4, **2010**.

[7] a) F. Bellina, S. Cauteruccio, L. Mannina, R. Rossi, S. Viel, *J. Org. Chem.* **2005**, *70*, 3997–4005; b) F. Bellina, M. Lessi, C. Manzini, *Eur. J. Org. Chem.* **2013**, 5621–5630; c) F. Bellina, N. Guazzelli, M. Lessi, C. Manzini, *Tetrahedron* **2015**, *71*, 2298–2305.

[8] For the chemistry of λ^3-iodanes, see: a) *Hypervalent Iodine Chemistry. Modern Developments in Organic Synthesis* (Ed.: T. Wirth), Springer, Berlin, **2003**; b) A. Yoshimura, V. V. Zhdankin, *Chem. Rev.* **2016**, *116*, 3328–3435.

[9] Examples include: a) I. Papoutsis, S. Spyroudis, A. Varvoglis, *Tetrahedron Lett.* **1996**, *37*, 913–916; b) I. Papoutsis, S. Spyroudis, A. Varvoglis, C. P. Raptopouloub, *Tetrahedron* **1997**, *53*, 6097–6112; for a mechanistic study, see: c) R. M. Moriarty, S. Tyagi, D. Ivanov, M. Constantinescu, *J. Am. Chem. Soc.* **2008**, *130*, 7564–7565.

[10] a) B. Y. Karele, S. V. Kalnin′, I. P. Grinberga, O. Ya. Neiland, *Chem. Hetercycl. Compd.* **1973**, *9*, 226–229; b) for a review, see: O. Neilands, *Chem. Hetercycl. Compd.* **2003**, *39*, 1555–1569.

[11] For the diaryliodonium renaissance, see: a) E. A. Merritt, B. Olofsson, *Angew. Chem. Int. Ed.* **2009**, *48*, 9052–9070; *Angew. Chem.* **2009**, *121*, 9214–9234; for recent examples of *NH*-pyrazole-based species, see b) M. Bielawski, J. Malmgren, L. M. Pardo, Y. Wikmark, B. Olofsson, *ChemistryOpen* **2014**, *3*, 19–22.

[12] a) K. Morimoto, Y. Ohnishi, A. Nakamura, K. Sakamoto, T. Dohi, Y. Kita, *Asian J. Org. Chem.* **2014**, *3*, 382–386; also see: b) T. Dohi, K. Morimoto, N. Takenaga, A. Goto, A. Maruyama, Y. Kiyono, H. Tohma, Y. Kita, *J. Org. Chem.* **2007**, *72*, 109–116; c) D. Lubriks, I. Sokolovs, E. Suna, *J. Am. Chem. Soc.* **2012**, *134*, 15436–15442; d) I. Sokolovs, D. Lubriks, E. Suna, *J. Am. Chem. Soc.* **2014**, *136*, 6920–6928; e) G. L. Tolnai, A. Székely, Z. Makó, T. Gáti, J. Daru, T. Bihari, A. Stirling, Z. Novák, *Chem. Commun.* **2015**, *51*, 4488–4491; f) R. Samanta, R. Narayan, J. O. Bauer, C. Strohmann, S. Sievers, A. P. Antonchick, *Chem. Commun.* **2015**, *51*, 925–928; g) S. G. Modha, M. F. Greaney, *J. Am. Chem. Soc.* **2015**, *137*, 1416–1419.

[13] a) E. A. Veretennikov, A. E. Gavrilov, *Chem. Heterocycl. Compd.* **2007**, *43*, 1081–1082 For *N*-Me imidazole derived iodane, see: b) N. Sh. Pirkuliyev, V. K. Brel, V. V. Zhdankin, N. S. Zefirov, *Rus. J. Org. Chem.* **2002**, *38*, 1224–1225.

[14] a) T. Dohi, M. Ito, K. Morimoto, Y. Minamitsuji, N. Takenaga, Y. Kita, *Chem. Commun.* **2007**, 4152–4154; b) T. Dohi, N. Yamaoka, I. Itani, Y. Kita, *Aust. J. Chem.* **2011**, *64*, 529–535.

[15] A 1,3 migration has also been proposed in pyrazole arylation by Ar_2I^+: Z. Gonda, Z. Novák, *Chem. Eur. J.* **2015**, *21*, 16801–16806.

[16] No scrambling between **2a**-d_2 and **2c** was observed at 50 °C in the absence of copper catalyst, see: a) B. Wang, R. L. Cerny, S. Uppaluri, J. J. Kempinger, S. G. DiMagno, *J. Fluorine Chem.* **2010**, *131*, 1113–1121; b) J. Malmgren, S. Santoro, N. Jalalian, F. Himo, B. Olofsson, *Chem. Eur. J.* **2013**, *19*, 10334–10342.

[17] The DFT calculations show equi-energetic binding of $Cu^{I}OTf$ to either of the two nitrogen sites.

[18] For copper-catalyzed *N*-arylation of azoles using diaryliodonium salts, see: S. K. Kang, S. H. Lee, D. Lee, *Synlett* **2000**, *7*, 1022–1024.

[19] a) For an early mechanistic study, see: T. P. Lockhart, *J. Am. Chem. Soc.* **1983**, *105*, 1940–1946; for a Cu^{I}-Cu^{III} cycle with hypervalent iodonium, see: b) R. J. Phipps, M. J. Gaunt, *Science*

2009, *323*, 1593; c) B. Chen, X. L. Hou, Y. X. Li, Y. D. Wu, *J. Am. Chem. Soc.* **2011**, *133*, 7668 – 7671; d) A. J. Hickman, M. S. Sanford, *Nature* **2012**, *484*, 177 – 185; e) N. Ichiishi, A. J. Canty, B. F. Yates, M. S. Sanford, *Organometallics* **2014**, *33*, 5525 – 5534; f) M. G. Suero, E. D. Bayle, B. S. L. Collins, M. J. Gaunt, *J. Am. Chem. Soc.* **2013**, *135*, 5332 – 5335.

[20] For Cu^{III}, see: A. Casitas, X. Ribas, *Chem. Sci.* **2013**, *4*, 2301 – 2318.

[21] All solid state X-Ray structures have been deposited with the Cambridge Structural Database at CCDC 1465191-1465196.

[22] a) A. Klapars, J. C. Antilla, X. Huang, S. L. Buchwald, *J. Am. Chem. Soc.* **2001**, *123*, 7727 – 7729; b) M. Wang, Z. Zhang, F. Xie, W. Zhang, *Chem. Commun.* **2014**, *50*, 3163 – 3165.

[23] a) A. Krasovskiy, P. Knochel, *Angew. Chem. Int. Ed.* **2004**, *43*, 3333 – 3336; *Angew. Chem.* **2004**, *116*, 3396 – 3399; for the use of *i*PrMgCl·LiCl in borylation, see: b) E. Demory, V. Blandin, J. Einhorn, P. Y. Chavant, *Org. Process Res. Dev.* **2011**, *15*, 710 – 716; c) P. A. Bethel, A. D. Campbell, F. W. Goldberg, P. D. Kemmitt, G. M. Lamont, A. Suleman, *Tetrahedron* **2012**, *68*, 5434 – 5444.

Received: March 13, 2016
Published online: May 3, 2016

